NeoImmuneTech
6 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC (NCT04984811) | NeoImmuneTech | 2021-11-15 |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy (NCT05075603) | NeoImmuneTech | 2021-07-29 |
| NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma (NCT04594811) | NeoImmuneTech | 2021-01-21 |
| A Trial of NT-I7 in COVID-19 (SPESELPIS) (NCT04501796) | NeoImmuneTech | 2020-11-27 |
| NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (NCT04332653) | NeoImmuneTech | 2020-06-10 |
| High-Risk Skin Cancers With Atezolizumab Plus NT-I7 (NCT03901573) | NeoImmuneTech | 2019-12-26 |
Track NeoImmuneTech automatically
Every clearance here is in the API, with alerts when new ones post.